Advanced glycation end products and the kidney

被引:301
|
作者
Bohlender, JM [1 ]
Franke, S [1 ]
Stein, G [1 ]
Wolf, G [1 ]
机构
[1] Univ Klin Jena, Innere Med Klin 3, Dept Internal Med 3, Jena, Germany
关键词
RAGE; diabetic nephropathy; progression of renal disease; inflammation; glycoxidation;
D O I
10.1152/ajprenal.00398.2004
中图分类号
Q4 [生理学];
学科分类号
071003 ;
摘要
Advanced glycation end products (AGEs) are a heterogeneous group of protein and lipids to which sugar residues are covalently bound. AGE formation is increased in situations with hyperglycemia ( e. g., diabetes mellitus) and is also stimulated by oxidative stress, for example in uremia. It appears that activation of the renin-angiotensin system may contribute to AGE formation through various mechanisms. Although AGEs could nonspecifically bind to basement membranes and modify their properties, they also induce specific cellular responses including the release of profibrogenic and proinflammatory cytokines by interacting with the receptor for AGE ( RAGE). However, additional receptors could bind AGEs, adding to the complexity of this system. The kidney is both: culprit and target of AGEs. A decrease in renal function increases circulating AGE concentrations by reduced clearance as well as increased formation. On the other hand, AGEs are involved in the structural changes of progressive nephropathies such as glomerulosclerosis, interstitial fibrosis, and tubular atrophy. These effects are most prominent in diabetic nephropathy, but they also contribute to renal pathophysiology in other nondiabetic renal diseases. Interference with AGE formation has therapeutic potential for preventing the progression of chronic renal diseases, as shown from data of animal experiments and, more recently, the first clinical trials.
引用
收藏
页码:F645 / F659
页数:15
相关论文
共 50 条
  • [1] Advanced glycation end-products and the kidney
    Busch, Martin
    Franke, Sybille
    Ruester, Christiane
    Wolf, Gunter
    EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2010, 40 (08) : 742 - 755
  • [2] Advanced glycation end products and receptor for advanced glycation end products in AA amyloidosis
    Röcken, C
    Kientsch-Engel, R
    Mansfeld, S
    Stix, B
    Stubenrauch, K
    Weigle, B
    Bühling, F
    Schwan, M
    Saeger, W
    AMERICAN JOURNAL OF PATHOLOGY, 2003, 162 (04): : 1213 - 1220
  • [3] Advanced glycation end products in the pathogenesis of chronic kidney disease
    Rabbani, Naila
    Thornalley, Paul J.
    KIDNEY INTERNATIONAL, 2018, 93 (04) : 803 - 813
  • [4] Advanced Glycation End Products
    Thomas, Merlin C.
    DIABETES AND THE KIDNEY, 2011, 170 : 66 - 74
  • [5] The Potential Role of Advanced Glycation End Products in the Development of Kidney Disease
    Ma, Yibin
    Wang, Xinyu
    Lin, Shan
    King, Lei
    Liu, Liegang
    NUTRIENTS, 2025, 17 (05)
  • [6] Dietary Advanced Glycation End Products and Risk of Chronic Kidney Disease
    Ejtahed, Hanieh-Sadat
    Angoorani, Pooneh
    Asghari, Golaleh
    Mirmiran, Parvin
    Azizi, Fereidoun
    JOURNAL OF RENAL NUTRITION, 2016, 26 (05) : 308 - 314
  • [7] Hypoxia in the Diabetic Kidney Is Independent of Advanced Glycation End-Products
    Nordquist, Lina
    Liss, Per
    Fasching, Angelica
    Hansell, Peter
    Palm, Fredrik
    OXYGEN TRANSPORT TO TISSUE XXXIV, 2013, 765 : 185 - 193
  • [8] Advanced Glycation End Products, Soluble Receptor for Advanced Glycation End Products, and Risk of Colorectal Cancer
    Jiao, Li
    Taylor, Philip R.
    Weinstein, Stephanie J.
    Graubard, Barry I.
    Virtamo, Jarmo
    Albanes, Demetrius
    Stolzenberg-Solomon, Rachael Z.
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2011, 20 (07) : 1430 - 1438
  • [9] Advanced glycation end products in uremia
    Henle, T
    Miyata, T
    ADVANCES IN RENAL REPLACEMENT THERAPY, 2003, 10 (04): : 321 - 331
  • [10] Advanced Glycation End Products and Psoriasis
    Maurelli, Martina
    Gisondi, Paolo
    Girolomoni, Giampiero
    VACCINES, 2023, 11 (03)